Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 6.62B P/E - EPS this Y -17.00% Ern Qtrly Grth -
Income -456M Forward P/E 14.01 EPS next Y 39.80% 50D Avg Chg -2.00%
Sales 4.5B PEG 16.09 EPS past 5Y - 200D Avg Chg 11.00%
Dividend N/A Price/Book 0.95 EPS next 5Y 1.50% 52W High Chg -14.00%
Recommedations 1.00 Quick Ratio 0.77 Shares Outstanding 351.90M 52W Low Chg 48.00%
Insider Own 88.50% ROA 0.96% Shares Float 40.96M Beta 0.46
Inst Own 11.75% ROE -6.50% Shares Shorted/Prior 2.21M/1.68M Price 18.91
Gross Margin 60.85% Profit Margin -10.15% Avg. Volume 494,900 Target Price 27.18
Oper. Margin 3.04% Earnings Date Jul 31 Volume 1,023,819 Change -2.27%
About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Corporation News
09/16/24 Stocks to Watch Monday: DJT, Apple, Pfizer, Intel
09/16/24 Bausch + Lomb explores sale amid parent company's debt woes - report
08/09/24 Bausch + Lomb Insider Ups Holding During Year
08/07/24 Insider Buying: CEO Brent Saunders Acquires Shares of Bausch & Lomb Corp
07/31/24 Bausch + Lomb Announces Second-Quarter 2024 Results
07/11/24 Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31
07/08/24 Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief
06/17/24 Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
06/10/24 Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
06/03/24 Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States
05/29/24 Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
05/28/24 Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®
05/28/24 Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
05/03/24 Bausch + Lomb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
05/01/24 Bausch & Lomb Corp (BLCO) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Net Loss Widening
05/01/24 Bausch + Lomb Announces First-Quarter 2024 Results
04/29/24 Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
04/25/24 Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
04/18/24 Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
04/15/24 Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
BLCO Chatroom

User Image vcd103 Posted - 3 hours ago

$BHC this direct sale of $BLCO could be n orchestrated 4 yrs ago and spared shareholders from opportunity costs from poor Board and CEO leadership. I have been investing for many decades and this one is an epic cluster..

User Image nabisko7 Posted - 3 hours ago

$BHC where are our $BLCO shares??

User Image SellSalix Posted - 4 hours ago

$BHC I’ve read that private equity firms interested in acquiring $BLCO must declare their bids by the end of today. Firms such as Blackstone, Advent International, and TPG are among those expected to participate. I believe Alcon’s EV/Ebitda ratio is no less than 20; maybe as high as 28. BLCO is not as big and profitable as ALC and it has more debt than ALC. So, it clearly deserves a discount to them. Just not sure how much of a discount as I’m no pro, but let’s be conservative and assume it could fetch 13 times adj ebidta, BHC could generate almost $12b in proceeds (though probably less b/c of tax). This should propel the stock to the $18 level, or more if Xifaxan’s exclusivity is ensured through to end of 2027.

User Image lookingforfraud Posted - 5 hours ago

$BHC From Carl smacking Ackman senseless and throwing him in the dumpster all wounded and making him get out, to this stupid Papa joke... To a youngster analyst calling the shots on share price... To why the heck don't I get my $blco shares... And then Sanders.. What a freaking ride.

User Image copywrites Posted - 6 hours ago

$BHC $BLCO printed again at 20$ ... interesting 🤔 coincidence?

User Image Hshshhssos Posted - 7 hours ago

$BHC interesting reading through a study done on going private transactions from 2022. 8 of the transactions were valued over $10bn and the mean multiple was 25.1x. Considering $BLCO and current market conditions what do we think is a fair multiple?

User Image joaocastilho Posted - 8 hours ago

$BHC the rumours of restructuring made it crash to a minimum of 4/share and it's now at 8+ (strong likelihood of $BLCO going private).

User Image jParkz Posted - 1 day ago

$BLCO News Article (BLCO) Technical Pivots with Risk Controls https://marketwirenews.com/news-releases/-blco-technical-pivots-with-risk-controls-8933185627656575.html $BLCO

User Image FartsDust Posted - 1 day ago

$BLCO key will be seeing if it can hold 20

User Image smartkarma Posted - 1 day ago

$BLCO | Eyeing a Sale? Could Bausch + Lomb’s Innovations and Revenue Surge Spark a Takeover Battle? "Bausch + Lomb Corporation has long established itself as a global leader in eye health, offering a wide range of products across pharmaceuticals,..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/eyeing-a-sale-could-bausch-lomb-s-innovations-and-revenue-surge-spark-a-takeover-battle

User Image StageAnalysis Posted - 1 day ago

New Blog Post: US Stocks Watchlist – 17 September 2024 There were 13 stocks highlighted from the US stocks watchlist scans today – $BLCO, $FSLR, $LYFT #stocks #trading #investing https://www.stageanalysis.net/blog/1199395/us-stocks-watchlist-17-september-2024

User Image SellSalix Posted - 1 day ago

@btradingwarehouse no way u see these levels unless they can sell $BLCO for $16b or more

User Image HammerstoneMarkets Posted - 2 days ago

$BLCO +3.71% after y'day's +14% gain following an article on Saturday in the @FT stating that Bausch + Lomb is exploring a sale to separate itself from parent Bausch Health ( $BHC). This morning: -A Jefferies note said a sale would be a big positive for $BHC's (Buy, $9 PT) equity & debt shareholders. On Monday: -Wells Fargo said a sale "makes sense to us given the steep valuation discount between $BLCO (OW, $23 PT) and its closest eye care peers." -JPMorgan disagreed, saying the valuation discount (vs $COO & $ALC) is warranted b/c 70% of $BLCO's (Neutral) earnings emanate from their drug units & not eye care units. - $BHC -shares are +12.6% over the past 2 days

User Image stevenlarrykaye Posted - 2 days ago

$BLCO $BHC blocked

User Image TheDayTradingAcademy Posted - 2 days ago

The U.S. contact lens provider $BLCO founded in 1853, shares rose +14.47% on Monday at $17.80, after the Financial Times reported it was considering a sale. Bausch + Lomb is working with $GS advisors & is expected to catch the attention of private equity. The stock is +19.4% in the past 3 months, +4.34% in 2024 & +0.91% y/y, with a market cap of $5.47B.

User Image nabisko7 Posted - 2 days ago

$BHC where are our $BLCO shares from the spinoff???

User Image jParkz Posted - 3 days ago

News out $BLCO Why Bausch + Lomb Rallied Today https://marketwirenews.com/news-releases/why-bausch-lomb-rallied-today-5342983295108390.html $BLCO

User Image tradethehalt Posted - 3 days ago

$BLCO Bausch + Lomb Stock Soars on Sale Reports https://www.fool.com/investing/2024/09/16/why-bausch-lomb-rallied-today/

User Image vcd103 Posted - 3 days ago

@momos @Jemz exit for me was approximately $35 combined value of whatever is left post spin-off or outright sale of $BLCO. Will be interesting to see how this unfolds by 1Q2025

User Image nabisko7 Posted - 3 days ago

$BHC they will sell $BLCO and we will get nothing. No shares for us

User Image midasilv Posted - 3 days ago

$BHC will this damn despicable dumpster diver finally return some value to its long-suffering shareholders if $BLCO is sold for a good price?

User Image StocktwitsNews Posted - 3 days ago

Bausch + Lomb Stock Surges On Report Of Potential Sale: Retail Cheers Even As Analysts Assess Impact. $BLCO $BHC https://stnews.onelink.me/4nY0/ee90r6r7

User Image JaumeIII Posted - 3 days ago

@jbal Yes, read that over the weekend...$blco stuck in limbo. And they made a huge mistake buying Xiidra...

User Image JaumeIII Posted - 3 days ago

$CLSD It would make so much sense, as Map has pointed out repeatedly, for $abbv to buy or partner with clsd to complete its P3 pivotal study if P2 results are what we expect. At this price, with what clsd brings to the table, it's a no brainer. If not abbv, $regn would make the most sense...Unfortunately, $blco is kind of stuck with $bhc. Either way, any price under 1.35 is a bargain and undoubtedly talks are underway.

User Image Contrarian_Dan Posted - 3 days ago

$BLCO nice!!!

User Image vcd103 Posted - 3 days ago

$BHC this $BLCO outright sale might just get this moving towards $7.5

User Image theflynews Posted - 3 days ago

Morning Movers: Bausch + Lomb surges as said to consider potential sale - $BLCO - https://thefly.com/permalinks/entry.php/BLCOid3983956

User Image StockElementCorporation Posted - 3 days ago

Premarket movers 📈 $ZNTL +37% $APVO +34% $VRAX +30% $ASND +20% $BLCO +20% REE +9% SATS +7% COSM +5% GTLS +4% ZG +4% RLAY +3% BLDR +3% SBT -9% FOLLOW US FOR MORE LEVELS & ALERTS 📈

User Image topstockalerts Posted - 3 days ago

Pre Market Top Gainers PT2 $ATPC $APVO $NUVL $BLCO $ASND

Analyst Ratings
Needham Hold Sep 16, 24
RBC Capital Outperform Aug 5, 24
HC Wainwright & Co. Buy Aug 5, 24
Deutsche Bank Hold Aug 1, 24
RBC Capital Outperform Aug 1, 24
Needham Hold Aug 1, 24
Raymond James Outperform Jul 10, 24
Evercore ISI Group In-Line Jul 2, 24
Morgan Stanley Overweight May 6, 24